论文部分内容阅读
伊伐布雷定是一种新型减慢心率药物,对快速性心律失常有潜在的治疗作用。伊伐布雷定特异性地抑制起搏电流(If),降低窦房结节律,对不适当窦性心动过速及体位性心动过速综合征的治疗有一定的作用。伊伐布雷定能降低心肌细胞自发动作电位的频率,减慢房室结的传导速度,可能减少心房颤动的发生并且控制心室率,其临床疗效观察存在不一致性,其疗效有待观察。伊伐布雷定通过抑制超极化激活环核苷酸门控通道(HCN)通道介导的If增加,其可能减少室性心律失常的发生率,降低心室颤动阈值,其临床疗效有待验证。
Ivabradine is a new type of heart rate-lowering drug that has a potential therapeutic effect on tachyarrhythmia. Ivabradine specifically inhibits pacing current (If) and reduces sinus node rhythm, which may play a role in the treatment of inappropriate sinus tachycardia and orthostatic tachycardia syndrome. Ivabradine can reduce the frequency of spontaneous action potential of cardiomyocytes, slow down the conduction velocity of atrioventricular node, may reduce the occurrence of atrial fibrillation and control ventricular rate, the clinical efficacy of the observed inconsistency, its efficacy remains to be seen. Ivabradine inhibits the hyperpolarization-activated cyclic nucleotide gate (HCN) channel-mediated increase in If, which may reduce the incidence of ventricular arrhythmias and reduce the threshold of ventricular fibrillation, the clinical efficacy of which remains to be verified.